These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 16537830)

  • 1. Impact of a scientific presentation on community treatment patterns for primary breast cancer.
    Giordano SH; Duan Z; Kuo YF; Hortobagyi GN; Freeman J; Goodwin JS
    J Natl Cancer Inst; 2006 Mar; 98(6):382-8. PubMed ID: 16537830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: changes in practice patterns after publication of Cancer and Leukemia Group B 9343.
    Palta M; Palta P; Bhavsar NA; Horton JK; Blitzblau RC
    Cancer; 2015 Jan; 121(2):188-93. PubMed ID: 25488523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of CALGB 9343 Trial and Sociodemographic Variation on Patterns of Adjuvant Radiation Therapy Practice for Elderly Women (≥70 Years) with Stage I, Estrogen Receptor-positive Breast Cancer: Analysis of the National Cancer Data Base.
    Chu QD; Zhou M; Medeiros KL; Peddi P; Wu XC
    Anticancer Res; 2017 Oct; 37(10):5585-5594. PubMed ID: 28982874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant therapy for breast cancer: practice patterns of community physicians.
    Harlan LC; Abrams J; Warren JL; Clegg L; Stevens J; Ballard-Barbash R
    J Clin Oncol; 2002 Apr; 20(7):1809-17. PubMed ID: 11919238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
    Bedard PL; Di Leo A; Piccart-Gebhart MJ
    Nat Rev Clin Oncol; 2010 Jan; 7(1):22-36. PubMed ID: 19997076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg.
    Hudis C
    Clin Breast Cancer; 2002 Dec; 3(5):326-32. PubMed ID: 12533262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).
    Saloustros E; Malamos N; Boukovinas I; Kakolyris S; Kouroussis C; Athanasiadis A; Ziras N; Kentepozidis N; Makrantonakis P; Polyzos A; Christophyllakis C; Georgoulias V; Mavroudis D
    Breast Cancer Res Treat; 2014 Dec; 148(3):591-7. PubMed ID: 25399229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.
    Dinan MA; Mi X; Reed SD; Hirsch BR; Lyman GH; Curtis LH
    JAMA Oncol; 2015 May; 1(2):158-66. PubMed ID: 26181015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort.
    Elkin EB; Hurria A; Mitra N; Schrag D; Panageas KS
    J Clin Oncol; 2006 Jun; 24(18):2757-64. PubMed ID: 16782916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients.
    Bria E; Nistico C; Cuppone F; Carlini P; Ciccarese M; Milella M; Natoli G; Terzoli E; Cognetti F; Giannarelli D
    Cancer; 2006 Jun; 106(11):2337-44. PubMed ID: 16649217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taxanes in the adjuvant treatment of breast cancer: why not yet?
    Piccart MJ; Lohrisch C; Duchateau L; Buyse M
    J Natl Cancer Inst Monogr; 2001; (30):88-95. PubMed ID: 11773299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Impact of CALGB 9343 on Radiation Utilization.
    Squeo G; Malpass JK; Meneveau M; Balkrishnan R; Desai RP; Lattimore C; Anderson RT; Showalter SL
    J Surg Res; 2020 Dec; 256():577-583. PubMed ID: 32805580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of taxanes in breast cancer chemotherapy: what's new 15 years after?].
    Herceg D; Vrbanec D
    Lijec Vjesn; 2009; 131(5-6):133-41. PubMed ID: 19642533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of evidence-based clinical guidelines on the adoption of postmastectomy radiation in older women.
    Shirvani SM; Pan IW; Buchholz TA; Shih YC; Hoffman KE; Giordano SH; Smith BD
    Cancer; 2011 Oct; 117(20):4595-605. PubMed ID: 21710653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.
    Harlan LC; Clegg LX; Abrams J; Stevens JL; Ballard-Barbash R
    J Clin Oncol; 2006 Feb; 24(6):872-7. PubMed ID: 16484696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.
    Dumontet C; Krajewska M; Treilleux I; Mackey JR; Martin M; Rupin M; Lafanechère L; Reed JC
    Clin Cancer Res; 2010 Aug; 16(15):3988-97. PubMed ID: 20576719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
    National Institutes of Health Consensus Development Panel
    J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.